Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials

Horn, Nancy A., Meek, Jennifer A., Budahazi, Gregg, Marquet, Magda·1995·Human Gene Therapy

Abstract

A production method has been developed for the purification of pharmaceutical-grade plasmid DNA for in vivo gene therapy. This method has been applied to the purification of VCL-1005, which is a eukaryotic plasmid expression vector that codes for the production of the HLA-B7 protein. Purified VCL-1005 is formulated with a cationic lipid and injected directly into established tumors of HLA-B7-negative patients with advanced cancers to heighten the patient's immune response against the cancer. The purification of pharmaceutical-grade plasmid DNA requires the development of highly reproducible and scaleable processing methods that meet regulatory standards similar to those required for the manufacture of recombinant protein pharmaceuticals. Defined pharmaceutical standards of purity, potency, efficacy, and safety are routinely met by the process described in this study. The scaleable purification method described here is a combination of highly reproducible unit operations; alkaline lysis, precipitation, and size-exclusion chromatography. The advantages over existing DNA purification methods include improved plasmid purity and the elimination of undesirable process additives such as toxic organic extractants and animal-derived enzymes. The overall process yield of purified plasmid DNA from fermentation through final column purified product is greater than 50%. Contaminating Escherichia coli DNA levels are reproducibly below 1% as measured by Southern analysis. Endotoxin levels are less than 0.03 endotoxin units/μg plasmid DNA and residual protein is undetectable. This process was used to produce 100 mg of VCL-1005 for use in an active clinical protocol. A scaleable method for the production of highly purified plasmid DNA has been developed. The method takes into consideration all applicable regulations and guidelines that apply to the manufacture of an injectable drug substance. The unit operations are simple and reliable and can be used to generate high-purity plasmid DNA. The product is free of host Escherichia coli RNA. Contaminating E. coli DNA and endotoxins are reduced to trace levels without the use of toxic extraction techniques or animal-derived enzymes. The unit operations are an alkaline-mediated cell lysis, 2-propanol precipitation, ammonium acetate precipitation, PEG-8000 precipitation, column chromatography, and final aseptic processing to produce a sterile drug substance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1995.6.5-565

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 243

Metadata

Authors
Horn, N. A., Meek, J. A., Budahazi, G., & Marquet, M.
Venue
Human Gene Therapy
Published
1995-05
Volume
6
Issue
5
Pages
565-573
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2017702389
Cited by
243
References
1
FWCI
3.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials. https://app.cochat.ai/papers/10.1089/hum.1995.6.5-565
The paper
Horn, N. A., Meek, J. A., Budahazi, G., & Marquet, M. (1995). Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials. Human Gene Therapy. https://doi.org/10.1089/hum.1995.6.5-565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.